Masimo’s Low-Profile Infant, Neonatal Pulse-Ox Sensors

Masimo officials announce the full market release of low-profile sensors to monitor oxygen saturation in newborns. The newly enhanced low-profile LNCS, M-LNCS Neo, NeoPt, and Inf Sensors are smaller and thinner, making them significantly more comfortable for patients and easier to apply for healthcare workers.

Masimo's breakthrough infant and neonatal sensor enhancements offer stellar performance, reliability, and accuracy, as well as compatibility with Masimo's noninvasive SET and rainbow SET technologies, which continuously monitor oxygenation, pulse rate, and blood constituent measurements that previously required invasive or complicated procedures.

"Masimo's new low-profile sensors are not only flatter and easier to apply, but the added pliability allows them to fit around the extremities better, so they stay on better," states Elizabeth Berube, patient care coordinator with University Health System-San Antonio, a 498-bed hospital. "When a baby's only a pound and a half at birth, it makes a difference to have this little, more streamlined sensor."

Masimo's breakthrough low-profile sensor components perform to the highest standards clinicians the world over have come to expect from Masimo SET Measure-through Motion and Low Perfusion pulse oximetry.

Blood-oxygen monitoring plays a key role in maintaining the health of newborns. Too little oxygen can lead to brain damage, organ failure or death; too much oxygen can cause blindness. A multi-center study published in the international peer-reviewed academic journal Acta Paediatrica showed that a change in clinical practice with the use of Masimo SET pulse oximetry technology led to a significant reduction of severe retinopathy of prematurity (ROP) – a devastating eye disorder resulting in partial or complete blindness in premature newborns. The study also confirmed that conventional pulse oximetry technology is not effective in reducing ROP, even when clinical practice is changed to reflect lowered oxygen saturation targets.(1)

Joe Kiani, Masimo CEO and chairman of the Board, states: "The release of our new line of low-profile sensors will enable clinicians to better care for their newborn patients, and offer the most vulnerable of our population a greater chance of leading healthy lives. We're proud to deliver another industry first – a line of low-profile, extremely small and highly effective sensors for healthcare providers worldwide."

(1)Castillo A., Deulofeut R., Critz A., Sola A. "Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology." Acta Paediatrica.2011 Feb; 100 (2): 188–192.